<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891267</url>
  </required_header>
  <id_info>
    <org_study_id>DSE-866/46</org_study_id>
    <secondary_id>2007-003130-41 EudraCT number</secondary_id>
    <nct_id>NCT00891267</nct_id>
  </id_info>
  <brief_title>Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome</brief_title>
  <acronym>VAMOS</acronym>
  <official_title>Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of two doses of olmesartan medoxomil and
      amlodipine on vascular markers in hypertensive patients with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the anti-inflammatory effect of Olmesartan (OM) higher dose compared to Olmesartan (OM) lower dose and amlodipine (AML) on the change in levels of the inflammatory marker hs-CRP</measure>
    <time_frame>6 weeks for each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the additional antihypertensive efficacy in blood pressure (BP) lowering, assessed by conventional BP measurement and 24-h ambulatory BP measurement (24-h ABPM)</measure>
    <time_frame>6 weeks for each treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil tablets high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine taken once daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil tablets low dose</intervention_name>
    <description>Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks</description>
    <arm_group_label>Olmesartan medoxomil low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil tablets high dose</intervention_name>
    <description>Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks</description>
    <arm_group_label>Olmesartan medoxomil tablets high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine tablets taken once daily for 6 weeks</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female Europeans at the age of 18 years or above with hypertension, metabolic
             syndrome, and modest inflammation

          -  Blood pressure greater than or equal to 130/85 mmHg AND

          -  hs-CRP greater than or equal to 1.0 and less than 10.0 mg/dL AND at least two (2) of
             the following traits of the metabolic syndrome (ATP III criteria):

          -  abdominal obesity: waist circumference greater than 102 cm for men and 88 cm for
             women;

          -  triglyceride level greater than or equal to 150 mg/dL; HDL less than 40 mg/dL for men
             and less than 50 mg/dL for women

          -  fasting blood glucose greater than or equal to 110mg/dL

        Exclusion Criteria:

          -  Insulin depended diabetes or type-1 diabetes

          -  Severe or resistant hypertension

          -  Patients with secondary hypertension of any aetiology, such as renal disease,
             pheochromocytoma, or Cushing's syndrome

          -  Any acute or chronic inflammatory disease

          -  Constant use of lipid-lowering agents (eg statins, fibrates) for less than 3 months
             before study start

          -  Pregnant or lactating female patients of childbearing potential (prerequisite:
             adequate contraception);

          -  Patients with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the trial drug(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2009</study_first_posted>
  <last_update_submitted>May 24, 2011</last_update_submitted>
  <last_update_submitted_qc>May 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Senior Manager Clinical Development</name_title>
    <organization>Daiichi Sankyo Europe</organization>
  </responsible_party>
  <keyword>Inflammatory markers</keyword>
  <keyword>Vascular protection</keyword>
  <keyword>OM Effect</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

